PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
4.960
-0.170 (-3.31%)
At close: Oct 6, 2025, 4:00 PM EDT
5.03
+0.07 (1.41%)
After-hours: Oct 6, 2025, 5:03 PM EDT

Company Description

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.

Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy.

The company was founded in 2018 and is based in Boston, Massachusetts.

PepGen Inc.
PepGen logo
CountryUnited States
Founded2018
IPO DateMay 6, 2022
IndustryBiotechnology
SectorHealthcare
Employees81
CEOJames McArthur

Contact Details

Address:
321 Harrison Avenue, 8th Floor
Boston, Massachusetts 02118
United States
Phone781 797 0979
Websitepepgen.com

Stock Details

Ticker SymbolPEPG
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$12.00
CIK Code0001835597
CUSIP Number713317105
ISIN NumberUS7133171055
SIC Code2834

Key Executives

NamePosition
Dr. James G. McArthur Ph.D.President, Chief Executive Officer, Treasurer, Secretary and Director
Noel P. Donnelly M.B.A.Chief Financial Officer
Dr. Paul D. Streck M.B.A., M.D.Executive Vice President and Head of Research and Development
Dr. Michael Gait Ph.D.Founder and Scientific Advisory Board Member
Emiko BryantChief of Staff, Human Resources and Operations
Dr. Kasra Kasraian Ph.D.Chief Technology Officer
Dr. Hayley Parker Ph.D.Senior Vice President of Global Regulatory Affairs
Dr. Afsaneh Mohebbi Ph.D.Senior Vice President of Portfolio and Program Management

Latest SEC Filings

DateTypeTitle
Oct 3, 2025SCHEDULE 13GFiling
Oct 1, 20258-KCurrent Report
Oct 1, 2025SCHEDULE 13G/AFiling
Sep 30, 2025SCHEDULE 13D/AFiling
Sep 26, 20258-KCurrent Report
Sep 25, 2025424B5Filing
Sep 24, 2025424B5Filing
Sep 24, 20258-KCurrent Report
Aug 13, 2025SCHEDULE 13G/AFiling
Aug 7, 20258-KCurrent Report